바이러스 불활성화 시장 : 제품별, 방법별, 용도별, 최종사용자별 - 시장 예측(2026-2032년)

The Viral Inactivation Market is projected to grow by USD 1,484.30 million at a CAGR of 9.50% by 2032.

Viral Inactivation Market Introduction

Viral inactivation is a core bioprocessing control used to reduce the risk of adventitious and endogenous viruses in biologics, vaccines, plasma-derived therapies, cell and gene therapies, and recombinant proteins. The discipline is anchored in internationally recognized expectations, including ICH Q5A(R2), FDA biologics guidance, EMA quality requirements, WHO recommendations, and pharmacopeial standards that emphasize orthogonal viral safety controls across raw materials, manufacturing, and release.

For biopharmaceutical manufacturers, the viral inactivation market is shaped by rising biologics approvals, increasing demand for monoclonal antibodies and complex proteins, and sustained regulatory scrutiny of viral clearance validation. Low-pH hold, solvent-detergent treatment, pasteurization, and complementary filtration steps remain central to validated manufacturing strategies, while single-use systems and intensified processing are changing how viral inactivation is designed, monitored, and documented.

Transformative Shifts in Viral Inactivation

The viral inactivation landscape is shifting from conventional batch-centric processing toward more integrated, platform-based, and risk-based viral safety strategies. ICH Q5A(R2), adopted in 2023, reinforces lifecycle management, prior knowledge, and platform validation, which is particularly important for manufacturers producing multiple biologics through comparable unit operations.

Transformative change is also coming from continuous manufacturing, closed processing, and single-use technologies. These approaches can reduce contamination risk and improve operational flexibility, but they require tighter control of critical process parameters such as pH, temperature, exposure time, mixing, and hold conditions. As biologics pipelines expand into bispecific antibodies, viral vectors, recombinant vaccines, and next-generation proteins, viral inactivation strategies must be tailored to product sensitivity while still meeting robust viral clearance expectations.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing viral inactivation by improving process understanding, deviation detection, and predictive modeling. AI-enabled analytics can help correlate process parameters with viral clearance outcomes, identify process drift earlier, and support quality-by-design programs when trained on validated manufacturing and laboratory datasets.

The most practical near-term impact is in digital quality management, electronic batch record review, process monitoring, and experimental design for viral clearance studies. However, AI does not replace validated viral clearance testing. Regulators still expect scientifically justified models, representative scale-down studies, traceable data integrity, and documented human oversight before AI-derived insights can support GMP decisions.

Key Regional Insights for Viral Inactivation

North America remains a leading region for viral inactivation adoption due to the United States' large biologics manufacturing base, strong FDA oversight, extensive contract development and manufacturing infrastructure, and advanced capabilities in monoclonal antibodies, vaccines, and advanced therapies. Canada adds clinical manufacturing, vaccine development, and academic translational capacity, while Mexico is increasingly relevant for regional supply chain resilience, nearshoring of life sciences operations, and expanding pharmaceutical manufacturing integration.

Europe is defined by EMA-aligned quality expectations, mature GMP inspection systems, strong biologics clusters in Germany, France, Italy, Spain, and the United Kingdom, and advanced plasma fractionation and vaccine capabilities. Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, Singapore, and Australia invest in biologics, biosimilars, vaccines, clinical research, and contract manufacturing, supported by regulatory modernization and growing domestic healthcare demand. Latin America, led by Brazil and Mexico, is building local biologics and vaccine capacity to improve access and reduce import dependence, while the Middle East is prioritizing vaccine security, plasma self-sufficiency, and technology transfer through national health strategies. Africa is strengthening public health manufacturing infrastructure, regional vaccine initiatives, and biologics readiness, with viral inactivation becoming increasingly important for local production quality and global regulatory alignment.

Key Group Insights Across Global Alliances

ASEAN markets are strengthening regional biologics and vaccine capabilities through investments in Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, making standardized viral safety practices increasingly important for regional manufacturing, technology transfer, and regulatory reliance models. The GCC is advancing biomanufacturing, plasma programs, vaccine readiness, and localized pharmaceutical production as part of national health security, economic diversification, and pandemic preparedness strategies.

The European Union benefits from harmonized regulatory frameworks, mature quality systems, cross-border clinical research, and strong biologics manufacturing networks, making it a central reference point for viral clearance expectations. BRICS countries are central to biosimilars, vaccine production, local biologics scale-up, and cost-efficient manufacturing capacity, with China, India, Brazil, Russia, and South Africa each emphasizing health sovereignty and domestic supply. G7 countries continue to influence viral inactivation standards through regulatory science, GMP inspection practices, advanced manufacturing investments, and public health preparedness. NATO member states indirectly shape demand through biosecurity priorities, pandemic preparedness, resilient medical supply chains, coordinated health security planning, and investment in critical healthcare infrastructure.

Key Country Insights for Viral Inactivation

The United States leads viral inactivation demand through biologics innovation, FDA-regulated manufacturing, extensive clinical and commercial production capacity, and deep expertise in monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies. Canada supports vaccine, cell therapy, biologics research, and clinical manufacturing development, while Mexico is gaining relevance as a North American life sciences manufacturing partner. Brazil remains Latin America's key biologics and vaccine production hub, supported by public health manufacturing priorities, biosimilar adoption, and technology transfer programs.

In Europe, the United Kingdom contributes strong life sciences research, clinical development, and advanced therapy capabilities, while Germany combines engineering depth, biologics production, and rigorous quality systems. France has established vaccine, plasma-derived therapy, and biomanufacturing expertise; Italy supports pharmaceutical manufacturing, fill-finish, and biologics production; and Spain is strengthening biologics research, vaccine capacity, and contract manufacturing. Russia maintains domestic vaccine and biologics capabilities focused on supply security and national production. In Asia-Pacific, China and India drive biosimilar and vaccine scale-up through large manufacturing ecosystems and expanding regulatory capability, Japan emphasizes high-quality biologics, regulatory rigor, and process reliability, South Korea is a global leader in contract biomanufacturing and biosimilars, and Australia supports clinical trials, translational research, vaccine programs, and advanced therapy development.

Actionable Recommendations for Viral Inactivation Leaders

Industry leaders should align viral inactivation strategy with product modality, regulatory expectations, and lifecycle management from early development through commercial manufacturing. Building platform viral clearance packages, maintaining qualified scale-down models, and documenting prior knowledge can accelerate development while preserving compliance with ICH Q5A(R2), FDA, EMA, WHO, and pharmacopeial expectations.

Manufacturers should also invest in digital batch records, advanced analytics, single-use compatibility assessments, closed processing controls, and supplier qualification for critical raw materials. Cross-functional collaboration among process development, quality assurance, regulatory affairs, manufacturing science, and supply chain teams is essential to ensure that viral inactivation controls remain scientifically justified, inspection-ready, scalable, and resilient across global production networks.

Research Methodology

This executive summary is based on secondary research across regulatory guidance, pharmacopeial references, peer-reviewed literature, public regulatory documents, GMP inspection trends, and established bioprocessing industry sources. Key reference frameworks include ICH Q5A(R2), FDA and EMA biologics quality expectations, WHO guidance, and recognized viral clearance validation practices for biologics, vaccines, plasma-derived products, and recombinant therapies.

The research approach evaluates market dynamics by product modality, technology type, end user, geography, regulatory environment, and manufacturing model. Insights are validated through triangulation of public datasets, scientific consensus, regulatory documentation, and observed industry adoption patterns, with emphasis on evidence-backed interpretation rather than speculative market estimation, market sizing, market share, or forecasting.

Conclusion

Viral inactivation remains a foundational pillar of biologics safety and a strategic differentiator for manufacturers operating in regulated markets. As biologics portfolios diversify and global production networks expand, companies must combine proven viral clearance methods with modern process analytics, robust documentation, and harmonized quality systems.

The next phase of industry development will favor organizations that can validate viral inactivation efficiently, adapt to emerging modalities, and integrate digital tools without compromising regulatory confidence. Organizations that embed viral safety into process design, supply chain governance, technology transfer, and lifecycle management will be best positioned for resilient, compliant, and quality-driven growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Viral Inactivation Market, by Product

• 7.1. Consumables
  • 7.1.1. Chemical Kits
  • 7.1.2. Disinfectant Solutions
  • 7.1.3. Uv Lamps
• 7.2. Equipment
  • 7.2.1. Filtration Equipment
  • 7.2.2. Irradiation Equipment
  • 7.2.3. Sterilization Equipment

8. Viral Inactivation Market, by Method

• 8.1. Chemical Treatment
  • 8.1.1. Chlorine Dioxide
  • 8.1.2. Ethylene Oxide
  • 8.1.3. Hydrogen Peroxide
• 8.2. Heat Treatment
  • 8.2.1. Dry Heat
  • 8.2.2. Moist Heat
• 8.3. Physical Treatment
  • 8.3.1. Electron Beam
  • 8.3.2. Gamma Radiation
  • 8.3.3. Ultraviolet
    • 8.3.3.1. Low Pressure Mercury
    • 8.3.3.2. Pulsed Xenon

9. Viral Inactivation Market, by Application

• 9.1. Air Purification
  • 9.1.1. Hvac Systems
  • 9.1.2. Portable Purifiers
• 9.2. Food Processing
  • 9.2.1. Beverage Processing
  • 9.2.2. Dairy Processing
  • 9.2.3. Meat Processing
• 9.3. Pharmaceutical Manufacturing
  • 9.3.1. API Production
  • 9.3.2. Biologics Production
  • 9.3.3. Vaccine Production
• 9.4. Water Treatment
  • 9.4.1. Drinking Water Treatment
  • 9.4.2. Wastewater Treatment

10. Viral Inactivation Market, by End User

• 10.1. Biotechnology Firms
  • 10.1.1. Diagnostic Developers
  • 10.1.2. Therapeutics Developers
• 10.2. Food And Beverage Processors
  • 10.2.1. Beverage Plants
  • 10.2.2. Dairy Plants
  • 10.2.3. Meat Plants
• 10.3. Healthcare Facilities
  • 10.3.1. Clinics
  • 10.3.2. Hospitals
• 10.4. Laboratories
  • 10.4.1. Clinical Laboratories
  • 10.4.2. Research Laboratories

11. Viral Inactivation Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Viral Inactivation Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Viral Inactivation Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Asahi Kasei Medical
• 15.2. Charles River Laboratories International, Inc.
• 15.3. Clean Cells Inc.
• 15.4. Danaher Corporation
• 15.5. Eurofins Scientific SE
• 15.6. Kedrion
• 15.7. Lonza Group AG
• 15.8. Merck KGaA
• 15.9. METTLER TOLEDO
• 15.10. Pall Corporation
• 15.11. Parker Hannifin Corporation
• 15.12. Rad Source Technologies, Inc.
• 15.13. Sartorius AG
• 15.14. Texcell SA
• 15.15. Thermo Fisher Scientific Inc.
• 15.16. Vironova AB
• 15.17. WuXi Biologics